- Home
- / Eiger BioPharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Eiger BioPharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$8.5
2024-09-30
Market Capitalization
$2.6 M
2024-09-30
Revenue
$15.8 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 23, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.1M | 13.5M | 15.8M | |||||||
| Cost of goods sold | 745.0K | 1.8M | 24.0K | |||||||
| Gross profit | 11.6M | |||||||||
| Gross profit margin, % | 86.4% | |||||||||
| General and administrative expense | 10.3M | 12.4M | 13.1M | 12.0M | 14.0M | 17.1M | 20.6M | 23.9M | 29.1M | 25.2M |
| Operating expense total | 33.0M | 42.2M | 46.1M | 41.5M | 51.0M | 68.9M | 62.1M | 88.3M | 104.4M | 87.5M |
| EBIT | (33.0M) | (42.2M) | (46.1M) | (41.5M) | (51.0M) | (68.9M) | (62.1M) | (76.9M) | (92.7M) | (71.8M) |
| EBIT margin, % | -687.8% | |||||||||
| Interest income | 118.0K | 65.0K | 410.0K | 997.0K | 2.1M | 704.0K | 158.0K | 1.1M | 2.2M | |
| Interest expense | 5.5M | |||||||||
| Pre tax profit | (33.9M) | (96.8M) | (75.0M) | |||||||
| Income tax expense | 64.0K | 23.0K | 6.0K | |||||||
| Net Income | (33.9M) | (44.4M) | (47.1M) | (42.4M) | (52.4M) | (70.3M) | (65.1M) | (33.9M) | (96.8M) | (75.0M) |
| EPS | (2.3) | (50.0) |